Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DMTX

Dimension Therapeutics (DMTX) Stock Price, News & Analysis

Dimension Therapeutics logo

About Dimension Therapeutics Stock (NASDAQ:DMTX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$5.95
$5.95
50-Day Range
N/A
52-Week Range
$1.05
$6.10
Volume
N/A
Average Volume
150,214 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Remove Ads
Receive DMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dimension Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMTX Stock News Headlines

FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025
Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…
Pitch dimensions
KAYS - Kaya Holdings, Inc.
Anime Dimensions Codes (January 2023)
See More Headlines

DMTX Stock Analysis - Frequently Asked Questions

Dimension Therapeutics, Inc. (NASDAQ:DMTX) released its earnings results on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.20. The biotechnology company earned $4.48 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dimension Therapeutics investors own include Palatin Technologies (PTN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Aquinox Pharmaceuticals (AQXP), Bellicum Pharmaceuticals (BLCM) and Can-Fite BioPharma (CANF).

Company Calendar

Last Earnings
11/06/2017
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DMTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:DMTX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners